Bausch & Lomb wins FDA approval for Akreos implantable lens - BioOptics World
| RssImageAltText

Bausch & Lomb wins FDA approval for Akreos implantable lens


Sep 23, 2008

SEPTEMBER 23, 2008 -- Bausch & Lomb (Aliso Viejo, CA) has received US Food and Drug Administration (FDA) approval to market the Akreos Advanced Optics Aspheric Lens (model AO60) in the United States. The Akreos AO Lens is a single-piece, foldable acrylic intraocular lens with a four-haptic design and aspheric optics designed to be aberration-free. The lens is implanted with Bausch & Lomb's single-use AI-28 inserter, which enables single-handed insertion through an un-enlarged standard phaco incision.

Earlier this month, Bausch & Lomb announced an agreement with 20/10 Perfect Vision AG (Heidelberg, Germany) to form a joint venture focused on the laser vision correction. The company expects to begin shipping the Akreos AO Lens to surgical facilities by the end of September.

"I have been treating patients with the Akreos AO Lens for more than a year and a half in Canada and the single-piece four-haptic design allows for consistent post-op centration," said Rosa Braga-Mele, M.Ed, M.D., FRCSC. Dr. Braga-Mele serves as the director of the Cataract Unit and Surgical Teaching at Mt. Sinai Hospital in Toronto.

According to the company, the distinctive properties of the Akreos lens will serve as a pathway to microincision cataract surgery, enabling new lens technologies that can be inserted through smaller incisions.

More information:
Bausch & Lomb

Biophotonics Content Catigories:

Specialties                                                    Biomedical Imaging                          Techniques

Dermatology & Cosmetic SurgeryMicroscopySpectroscopy
OphthalmologyOCTCytometry & Cell Sorting
Oncology/CancerMolecular ImagingDNA Sequencing & Analysis
Cell Biology
More Specialties


Most Recommended Articles
Most Commented Articles